Cogent Biosciences

Yahoo Finance • 17 days ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 17 days ago

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Key Points Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter. Saturn V now holds 4.6 million... Full story

Yahoo Finance • 17 days ago

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Key Points Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn V now holds nearly 2.7 mill... Full story

Yahoo Finance • 18 days ago

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on... Full story

Yahoo Finance • 20 days ago

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective mea... Full story

Yahoo Finance • 23 days ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 28 days ago

MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26

(RTTNews) - Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle. Modular Medical, Inc. (MODD) shares surged... Full story

Yahoo Finance • last month

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress

We recently published 10 Market Movers That Made Millionaires in a Week. Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best-performing stocks of the past trading week. Cogent Biosciences skyrocketed by 126.3 percent week-on-week, a... Full story

Yahoo Finance • last month

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its partici... Full story

Yahoo Finance • last month

Cogent Biosciences Expects $547 Million in Net Proceeds From Equity, Convertible Notes Offerings

Cogent Biosciences (COGT) said Thursday it expects to raise about $546.8 million in net proceeds fro PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Cogent Biosciences announces proposed concurrent public offerings

* Cogent Biosciences (COGT [https://seekingalpha.com/symbol/COGT]) announced [https://seekingalpha.com/pr/20301289-cogent-biosciences-announces-proposed-concurrent-public-offerings-of-convertible-senior-notes] on Monday that it has comme... Full story

Yahoo Finance • last month

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Advance Monday Afternoon

Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p<0.0001) 46% Objective Response Rate (ORR) reported for bezuclastinib com... Full story

Yahoo Finance • 2 months ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results 

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA) filing for NonAdvSM re... Full story

Yahoo Finance • 2 months ago

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program; on-track for IND i... Full story

Yahoo Finance • 2 months ago

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated pre... Full story

Yahoo Finance • 2 months ago

Cogent gains FDA Breakthrough Therapy status for bezuclastinib

[FDA headquarters in Washington DC.] JHVEPhoto * The US FDA has granted Breakthrough Therapy designation for Cogent Biosciences' bezuclastinib for NonAdvanced Systemic Mastocytosis and Smoldering Systemic Mastocytosis. * The company p... Full story

Yahoo Finance • 2 months ago

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this year NDA submission for bezuclastinib p... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on Se... Full story